celecoxib

Overview

Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the nonsteroidal anti-inflammatory drug (NSAID) class, distinguished by its preferential blockade of the inducible COX-2 isoform over the constitutively expressed COX-1. By inhibiting COX-2, celecoxib suppresses the enzymatic conversion of arachidonic acid to prostaglandin H2, thereby reducing downstream synthesis of prostaglandin E2 (PGE2) and other pro-inflammatory eicosanoids. This mechanism underlies its well-established clinical use in managing pain, osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Compared to non-selective NSAIDs such as (RS)-ketoprofen or sulindac, celecoxib's COX-2 selectivity is associated with a reduced risk of gastrointestinal ulceration, making it a widely used reference compound in anti-inflammatory research. In preclinical and translational settings, its inhibition of the COX-2/PGE2 axis also positions it as a candidate for modulating neuroinflammation, cancer-related inflammation, and chemotherapy-induced adverse effects.

Beyond its canonical anti-inflammatory role, celecoxib has attracted growing interest as an oncological adjunct and a neurological therapeutic. Its ability to suppress proinflammatory cytokine signaling — including pathways involving TNF-α and interleukin-6 (IL-6) — and to downregulate Cyclooxygenase 2 (COX-2) (PTGS2/COX-2) expression at the transcriptional level has prompted investigation into its utility across a remarkably broad spectrum of diseases. The drug's well-characterized pharmacology and decades of clinical safety data make it a frequent positive control and benchmark comparator in studies evaluating novel anti-inflammatory and antitumor agents.

Recent Publications Summary

Recent studies have continued to evaluate celecoxib as a COX-2–targeted therapy in both preclinical and clinical settings. In a randomized, single-blind, placebo-controlled crossover trial in 12 healthy volunteers, 8-day pretreatment with celecoxib did not alter tramadol exposure after a single oral dose, but it reduced formation of O-desmethyltramadol, consistent with celecoxib’s reported weak CYP2D6 inhibition in vivo 42272128Jun. In another pharmacology-focused study, celecoxib was incorporated into a spatiotemporally programmed nanovesicle with gemcitabine to suppress tumor prostaglandin E2 signaling before inducing immunogenic cell death, thereby boosting dendritic cell maturation and antitumor immune priming in triple-negative breast cancer models 42236688Jun.

Several publications used celecoxib as a comparator or reference standard in anti-inflammatory and anticancer screening. Extracts and selenium nanoparticle preparations from Convolvulus oxyphyllus significantly down-regulated IL6 and COX2 expression, with effects described as comparable to celecoxib 42128884May. Likewise, a series of methoxylated 3,4-diarylpyrazoles showed anti-inflammatory activity in TPA-induced topical edema, and the most active analog surpassed celecoxib in inhibition while also reducing myeloperoxidase and proinflammatory cytokines including TNF-α, IL-1β, and IL-6 41894851Mar. In a separate medicinal chemistry study, newly synthesized pyrimidine derivatives were benchmarked against celecoxib and Diclofenac; the most potent compound showed slightly higher COX-2 potency and selectivity than celecoxib, while other analogues were comparable to it 41806609Mar. Celecoxib was also used as a reference in a study of thiadiazole derivatives, where docking scores comparable to celecoxib guided selection of compounds for in vivo analgesic and anti-inflammatory testing 41638094Feb. In vitro anticancer screening of NSAID-containing dendrons and dendrimers found that a sulindac-celecoxib Janus dendrimer was selectively active against MCF-7 cells 42167254May.

Other recent work focused on celecoxib’s therapeutic potential in disease models. In rats with paclitaxel-induced peripheral neuropathy, celecoxib attenuated thermal and mechanical hypersensitivity, improved histologic injury in dorsal root ganglia, sciatic nerve, and plantar skin, and downregulated COX-2, prostaglandin E2, and MHC expression; in vitro, it reduced DRG neuronal apoptosis and promoted survival, with effects comparable to COX-2 gene silencing 42048120Apr. Celecoxib was also studied as part of PrimeC, a fixed-dose oral combination with ciprofloxacin being evaluated in amyotrophic lateral sclerosis for mechanisms including neuroinflammation and iron homeostasis 41837970Mar. In oncology, a post hoc analysis examined long-term oncological outcomes and quality of life after combining celecoxib with low-dose-rate brachytherapy in prostate cancer, reflecting ongoing interest in celecoxib as an adjunct to (chemo)radiotherapy 41570179Jan.

What Changes, What Holds

1. Celecoxib can alter tramadol metabolism without changing parent-drug exposure, and it may be useful as a weak CYP2D6 probe rather than only a COX-2 inhibitor
NEW DIRECTION Celecoxib’s established anti-inflammatory role stands, but this adds a clinically relevant pharmacokinetic interaction signal: it reduced O-desmethyltramadol formation while leaving tramadol exposure unchanged 42272128Jun. That does not overturn the Overview, yet it broadens celecoxib’s understood effects beyond prostaglandin suppression and suggests weak in vivo CYP2D6 inhibition may matter in coadministration studies and possibly in practice.

2. Celecoxib remains a benchmark comparator, but some newer anti-inflammatory chemotypes now match or exceed it
REINFORCES The new screening papers mostly use celecoxib the way the Overview says it is used: as a reference standard for anti-inflammatory and anticancer work 42128884May41806609Mar. What changes is not celecoxib’s own mechanism, but the competitive landscape around it: several candidates were described as comparable to, or better than, celecoxib in COX-2 or cytokine-related readouts. That sharpens its role as a benchmark rather than adding a new biological function.

3. Celecoxib’s COX-2/PGE2 axis remains therapeutically relevant in neuropathy and oncology adjunct settings
REINFORCES The recent disease-model and combination-therapy studies extend, rather than challenge, the Overview’s account of celecoxib as a modulator of inflammation-linked pathology 42048120Apr41570179Jan. Its benefit in paclitaxel neuropathy fits the established COX-2/PGE2 framework, and the prostate-cancer analysis continues the long-standing interest in using celecoxib alongside radiotherapy. PrimeC and the dendrimer work add context, but they do not displace the baseline mechanism or use case.

Overview update candidates: celecoxib may weakly inhibit CYP2D6 in vivo and can reduce tramadol metabolite formation; its role as a comparator/reference standard is further entrenched; its COX-2/PGE2-linked utility extends to neuropathy and adjunct oncology settings.